



Introducing

TRIOKRISTM

Trientine Hydrochloride Capsules
USP (250 mg)

Triokris® – Precision in Chelation.

Manufactured in a USFDA-approved facility the
highest standards of safety and quality

 **Ikris**
Pharma Network
We Help You To Connect To The World

"An effective and well-tolerated copper chelator for long-term management of Wilson's Disease."

Incidence & Prevalence

“Rising awareness and genetic testing drive more diagnoses in children and young adults.”



Estimated

1 in 30,000-50,000

lives births worldwide.

<https://pubmed.ncbi.nlm.nih.gov/39535360/>

Estimated

1 in 18,678

(carrier frequency 1 in 67)
in Indian population.

Approx.

3,000–5,000

Over 70% of diagnosed cases
remain untreated in India.

Feature / Parameter	Triokris (Trientine)	D-Penicillamine	Zinc Therapy
Mechanism of Action	Chelates copper & promotes urinary excretion	Chelates copper & promotes urinary excretion	Blocks intestinal copper absorption
Indication	First-line alternative for Penicillamine-intolerant patients	First-line for symptomatic patients	Maintenance therapy or pre-symptomatic patients
Efficacy	Highly effective in reducing copper; comparable to Penicillamine	Highly effective initially	Slower effect; mainly maintenance
Side Effects	Less frequent severe side effects; rare lupus-like reaction, anemia	Rash, proteinuria, bone marrow suppression, lupus-like syndrome	Usually mild GI upset
Tolerance	Better tolerated by most patients	Poorly tolerated in some (~30%)	Well tolerated
Neurological Symptoms	Effective; lower risk of neurological worsening	Risk of initial neurological deterioration	Less effective for acute neurological symptoms

Mechanism of Action

- Trientine binds free copper ions and forms stable complexes.
- These complexes are excreted in urine, lowering tissue copper.
- Helps prevent re-accumulation of copper in organs.

Advantages of Triokris

- Chelation efficacy: Effectively lowers free copper levels.
- Tolerability: Lower incidence of hypersensitivity than D-penicillamine.
- Once stabilized therapy: Suitable for long-term maintenance.
- Gastro-safety: Minimal GI upset.

Clinical Evidence

- Trientine is a proven copper chelator for Wilson disease, effective in both hepatic and neurological forms.
- In comparative studies, efficacy was similar to D-penicillamine for improvement or stabilization of hepatic and neurological symptoms.¹
- Better tolerability — discontinuation rates were significantly lower with trientine (7.1%) than with penicillamine (28.8%).²
- Non-inferior maintenance efficacy demonstrated in the CHELATE trial, where trientine maintained copper control equivalent to penicillamine in stable patients.³
- Well-established long-term safety, making it the preferred alternative in patients intolerant to penicillamine or zinc therapy.⁴

Key References:

1. Walshe JM. Chelation treatment of Wilson's disease with trientine (triethylene tetramine dihydrochloride). QJM. 1982;51(2):83–96.

2. Weiss KH et al. Efficacy and safety of D-penicillamine and trientine in Wilson's disease: a retrospective cohort study. J Inherit Metab Dis. 2013;36(5):949–958.

3. Weiss KH et al. CHELATE trial: Noninferiority of trientine tetrahydrochloride vs D-penicillamine in stable Wilson disease. Hepatology. 2021;74(Suppl 1):1012A.

4. Taylor RM et al. Long-term outcomes of chelation therapy in Wilson disease. J Hepatol. 2019;71(1):109–117.

TRIOKRIS™

Composition :

- Each capsule contains: Trientine Hydrochloride 250 mg

Indication :

- For the treatment of Wilson's Disease in patient's intolerant to D-penicillamine or requiring alternative chelation therapy.

Pack Size :

- Triokris 250 mg - 100 capsules per pack.

Storage :

- Store in a light container & store below 25°C, protect from moisture and light.



Contact us

Ikris Pharma Network Pvt. Ltd 905 I-Thum Business Park, Block
A- 40 Sector 62 Nodia (UP) 201301
+91 81302 90915 / 1800 120 0365
info@ikrispharmanetwork.com

For More Info :

